Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

scientific article published on 18 December 2012

Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/MT.2012.258
P932PMC publication ID3594013
P698PubMed publication ID23247100
P5875ResearchGate publication ID233940848

P50authorTsukasa OhmoriQ73012013
P2093author name stringShuji Hishikawa
Keiya Ozawa
Yoichi Sakata
Hiroaki Mizukami
Akira Ishiwata
Jun Mimuro
Seiji Madoiwa
Fumiko Ono
Tomokazu Ikemoto
Asuka Sakata
P2860cites workEvidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.Q45859498
Update on progress and hurdles in novel genetic therapies for hemophiliaQ45872938
Specific detection of human coagulation factor IX in cynomolgus macaquesQ45873385
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.Q45882349
Hepatic venous compliance and role of liver as a blood reservoirQ46441130
Calculation of child and adult standard liver volume for liver transplantation.Q52342275
Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expansion in anaesthetized catsQ54487623
Gene therapy for the hemophiliasQ64377524
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapyQ24535690
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseQ29619095
AAV-mediated liver-directed gene therapy.Q33987462
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing ImmunityQ34069571
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.Q34168942
The hemophilias--from royal genes to gene therapyQ34276237
Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell lineQ34327402
Gene therapy for haemophilia.Q34530130
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.Q34994506
A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates.Q34994549
Adeno-associated virus antibody profiles in newborns, children, and adolescentsQ35191112
Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primatesQ35628868
Adenovirus-associated virus vector-mediated gene transfer in hemophilia BQ35691659
Clinical gene transfer studies for hemophilia A.Q35760801
Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liverQ35848563
Preclinical and clinical gene therapy for haemophiliaQ35915704
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospectsQ37146095
Immune responses to AAV in clinical trialsQ37873955
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophiliaQ39519818
Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structureQ39589248
Conceptual review of the hepatic vascular bed.Q39669839
Cardiorespiratory effects of rapid saline infusion in normal manQ40316981
Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapyQ41579770
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.Q41722852
Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectorsQ44258968
Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaquesQ45731350
Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques.Q45857121
P433issue2
P921main subjectvector-borne diseaseQ2083837
P304page(s)318-323
P577publication date2012-12-18
P1433published inMolecular TherapyQ15762400
P1476titleMinimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors
P478volume21

Reverse relations

cites work (P2860)
Q36713767Adeno-associated viral vectors for the treatment of hemophilia.
Q57170592Advances in gene therapy for hemophilia: basis, current status, and future perspectives
Q33830117CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
Q27014770Cardiovascular gene therapy for myocardial infarction
Q42271911Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors
Q38206852Current status of haemophilia gene therapy
Q30152887Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer
Q47554736Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Q41171011Flushing out antibodies to make AAV gene therapy available to more patients
Q99579530Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century
Q28081911Gene therapy for hemophilia
Q57167448Gene therapy for hemophilia: what does the future hold?
Q64246797Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency
Q37310450Gene therapy to treat cardiovascular disease
Q37236099Humoral Immune Response to AAV.
Q92863312Immune Response Mechanisms against AAV Vectors in Animal Models
Q36983740Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Q90000829Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates
Q33924645Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo
Q38543280New approaches to gene and cell therapy for hemophilia.
Q38529941Obstacles and future of gene therapy for hemophilia
Q42056009Overcoming preexisting humoral immunity to AAV using capsid decoys
Q38191212Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Q38684383Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity
Q36398678Strategies to circumvent humoral immunity to adeno-associated viral vectors
Q33902499The potential of adeno-associated viral vectors for gene delivery to muscle tissue
Q42261520The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals
Q40073271Unraveling the complex story of immune responses to AAV vectors trial after trial
Q89748411Utility of microminipigs for evaluating liver-mediated gene expression in the presence of neutralizing antibody against vector capsid

Search more.